ProPhase Labs, Inc. Marketable Securities, Unrealized Gain (Loss)
ProPhase Labs, Inc. (PRPH) reported Marketable Securities, Unrealized Gain (Loss) of $932.00 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-29.
Discontinued › Income Statement › Other Income
us-gaap:MarketableSecuritiesUnrealizedGainLoss · last filed 2023-03-29
- ProPhase Labs, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2022-06-30 was -$98.00K.
- ProPhase Labs, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2022-03-31 was $37.00K.
- ProPhase Labs, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2021-12-31 was -$53.00K.
- ProPhase Labs, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2021-09-30 was -$33.00K.
- ProPhase Labs, Inc. marketable securities, unrealized gain (loss) for fiscal 2022 was $932.00K.
- ProPhase Labs, Inc. marketable securities, unrealized gain (loss) for fiscal 2021 was -$164.00K.
- ProPhase Labs, Inc. marketable securities, unrealized gain (loss) for fiscal 2020 was -$9.00K, a 140.91% decline from fiscal 2019.
- ProPhase Labs, Inc. marketable securities, unrealized gain (loss) for fiscal 2019 was $22.00K, a 59.26% decline from fiscal 2018.
| Period end | Marketable Securities, Unrealized Gain (Loss) 3 month | Marketable Securities, Unrealized Gain (Loss) 6 month | Marketable Securities, Unrealized Gain (Loss) 9 month | Marketable Securities, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2022-12-31 | $932.00K 10-K · filed 2023-03-29 | |||
| 2022-06-30 | -$98.00K 10-Q · filed 2022-08-12 | -$61.00K 10-Q · filed 2022-08-12 | -$114.00K derived: sum of 3 quarters · filed 2023-03-29 | -$147.00K derived: sum of 4 quarters · filed 2023-03-29 |
| 2022-03-31 | $37.00K 10-Q · filed 2022-05-13 | -$16.00K derived: sum of 2 quarters · filed 2023-03-29 | -$49.00K derived: sum of 3 quarters · filed 2023-03-29 | -$116.00K derived: sum of 4 quarters · filed 2023-03-29 |
| 2021-12-31 | -$53.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | -$86.00K derived: sum of 2 quarters · filed 2023-03-29 | -$153.00K derived: sum of 3 quarters · filed 2023-03-29 | -$164.00K 10-K · filed 2023-03-29 |
| 2021-09-30 | -$33.00K 10-Q · filed 2021-11-12 | -$100.00K derived: sum of 2 quarters · filed 2022-08-12 | -$111.00K 10-Q · filed 2021-11-12 | -$118.00K derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-06-30 | -$67.00K 10-Q · filed 2022-08-12 | -$78.00K 10-Q · filed 2022-08-12 | -$85.00K derived: sum of 3 quarters · filed 2022-08-12 | -$93.00K derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | -$11.00K 10-Q · filed 2022-05-13 | -$18.00K derived: sum of 2 quarters · filed 2022-05-13 | -$26.00K derived: sum of 3 quarters · filed 2022-05-13 | -$31.00K derived: sum of 4 quarters · filed 2022-05-13 |
| 2020-12-31 | -$7.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | -$15.00K derived: sum of 2 quarters · filed 2022-03-31 | -$20.00K derived: sum of 3 quarters · filed 2022-03-31 | -$9.00K 10-K · filed 2022-03-31 |
| 2020-09-30 | -$8.00K 10-Q · filed 2021-11-12 | -$13.00K derived: sum of 2 quarters · filed 2021-11-12 | -$2.00K 10-Q · filed 2021-11-12 | $2.00K derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | -$5.00K 10-Q · filed 2021-08-13 | $6.00K 10-Q · filed 2021-08-13 | $10.00K derived: sum of 3 quarters · filed 2021-08-13 | $5.00K derived: sum of 4 quarters · filed 2021-08-13 |
| 2020-03-31 | $11.00K 10-Q · filed 2021-05-14 | $15.00K derived: sum of 2 quarters · filed 2021-05-14 | $10.00K derived: sum of 3 quarters · filed 2021-05-14 | $18.00K derived: sum of 4 quarters · filed 2021-05-14 |
| 2019-12-31 | $4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | -$1.00K derived: sum of 2 quarters · filed 2021-03-31 | $7.00K derived: sum of 3 quarters · filed 2021-03-31 | $22.00K 10-K · filed 2021-03-31 |
| 2019-09-30 | -$5.00K 10-Q · filed 2020-11-19 | $3.00K derived: sum of 2 quarters · filed 2020-11-19 | $18.00K 10-Q · filed 2020-11-19 | $18.00K derived: sum of 4 quarters · filed 2020-11-19 |
| 2019-06-30 | $8.00K 10-Q · filed 2020-08-11 | $23.00K 10-Q · filed 2020-08-11 | $23.00K derived: sum of 3 quarters · filed 2020-08-11 | $52.00K derived: sum of 4 quarters · filed 2020-08-11 |
| 2019-03-31 | $15.00K 10-Q · filed 2020-05-12 | $15.00K derived: sum of 2 quarters · filed 2020-05-12 | $44.00K derived: sum of 3 quarters · filed 2020-05-12 | $112.00K derived: sum of 4 quarters · filed 2020-05-12 |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | $29.00K derived: sum of 2 quarters · filed 2020-03-26 | $97.00K derived: sum of 3 quarters · filed 2020-03-26 | $54.00K 10-K · filed 2020-03-26 |
| 2018-09-30 | $29.00K 10-Q · filed 2019-11-12 | $97.00K derived: sum of 2 quarters · filed 2019-11-12 | $54.00K 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $68.00K 10-Q · filed 2019-08-12 | $25.00K 10-Q · filed 2019-08-12 | ||
| 2018-03-31 | -$43.00K 10-Q · filed 2019-05-14 | |||
| 2017-12-31 | -$78.00K 10-K · filed 2019-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |